Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) is one of 70 public companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare Guided Therapeutics to related companies based on the strength of its dividends, valuation, risk, institutional ownership, earnings, analyst recommendations and profitability.
Insider and Institutional Ownership
9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Guided Therapeutics | N/A | N/A | -138.23% |
Guided Therapeutics Competitors | -350.61% | -97.06% | -31.48% |
Earnings & Valuation
Gross Revenue | Net Income | Price/Earnings Ratio | |
Guided Therapeutics | $100,000.00 | -$3.49 million | -5.35 |
Guided Therapeutics Competitors | $1.06 billion | $91.09 million | -7.66 |
Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Guided Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 18.38, suggesting that their average share price is 1,738% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Guided Therapeutics and its peers, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Guided Therapeutics | 0 | 0 | 0 | 0 | N/A |
Guided Therapeutics Competitors | 259 | 780 | 1923 | 59 | 2.59 |
As a group, “Electromedical equipment” companies have a potential upside of 3,172.71%. Given Guided Therapeutics’ peers higher probable upside, analysts clearly believe Guided Therapeutics has less favorable growth aspects than its peers.
Summary
Guided Therapeutics peers beat Guided Therapeutics on 6 of the 10 factors compared.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.